SCHEMBL1939610

SCHEMBL1939610

Cn1cc(C(=O)c2cccc(NC(=O)Nc3ccc(Cl)cc3)c2)c2c(N)ncnc21

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.79
EGFR P00533 6/20 0.72
ERBB2 P04626 6/20 0.72
ERBB3 P21860 6/20 0.72
ERBB4 Q15303 6/20 0.72
TEK Q02763 6/20 0.72
NTRK1 P04629 4/20 0.55
KDR P35968 4/20 0.55
AURKA O14965 1/20 0.49
IKBKE Q14164 1/20 0.49
AURKB Q96GD4 1/20 0.49
NTRK2 Q16620 3/20 0.48
KCNH2 Q12809 1/20 0.48
NTRK3 Q16288 1/20 0.48
NPC1 O15118 1/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
KIT P10721 1/20 0.47
FLT3 P36888 1/20 0.46
RIPK1 Q13546 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1940880 0.93 PDGFRB (0.69) PDGFRBEGFRERBB2ERBB3ERBB4
SCHEMBL1939934 0.93 PDGFRB (0.68) PDGFRBEGFRERBB2ERBB3ERBB4
SCHEMBL1939951 0.92 PDGFRB (0.67) PDGFRBEGFRERBB2ERBB3ERBB4
SCHEMBL1940103 0.92 PDGFRB (0.67) PDGFRBEGFRERBB2ERBB3ERBB4
SCHEMBL1939914 0.91 PDGFRB (0.65) PDGFRBEGFRERBB2ERBB3ERBB4
SCHEMBL1940894 0.91 PDGFRB (0.65) PDGFRBEGFRERBB2ERBB3ERBB4
SCHEMBL1939844 0.90 EGFR (0.74) PDGFRBEGFRERBB2ERBB3ERBB4
SCHEMBL1941403 0.90 PDGFRB (0.64) PDGFRBEGFRERBB2ERBB3ERBB4
SCHEMBL1941221 0.89 PDGFRB (0.63) PDGFRBEGFRERBB2ERBB3ERBB4
SCHEMBL1940205 0.89 TEK (0.62) PDGFRBEGFRERBB2ERBB3ERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578751-B1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PROD INC (US) 2011-06-15 EP disclosed
US-7271262-B2 Pyrrolopyrimidine derivatives PFIZER INC (US) 2007-09-18 US disclosed
CN-1726218-A Pyrrolopyrimidine derivatives PFIZER PROD INC (US) 2006-01-25 CN disclosed
EP-1578751-A1 PYRROLOPYRIMIDINE DERIVATIVES Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20050037999-A1 Pyrrolopyrimidine derivatives PFIZER INC 2005-02-17 US disclosed
WO-2004056830-A1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037999-A1 Pyrrolopyrimidine derivatives CCNA1, CCNT1, TP53 PDGFRB 2465/4885EGFR 2758/4885ERBB2 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.